Table I.

Association between clinical parameters of the study population and CEACAM1 expression.

	CEACAM1 expression (IOD)
Clinical parameters	Number of samples	Median	Range	P-value
Histological grade
1	12	12,489	0–69,744	0.164
2	25	11,805	0–58,974
3	25	4,853	0–59,528
Histological type
Invasive duct carcinoma	42	6,400	0–59,528	0.038
Others	20	27,957	0–69,744
Tumor size
T1	25	9,347	0–58,974	0.363
T2	33	8,707	0–69,744
T3	4	2,513	0–32,286
Lymph node metastasis
No	39	19,248	0–69,744	0.017
Yes	23	5,025	0–59,528
Age, years
<50	15	7,884	0–59,528	0.710
≥50	47	8,707	0–69,744
Estrogen receptor status
Negative	26	11,321	0–55,320	0.414
Positive	36	6,400	0–69,744
Progesterone receptor status
Negative	33	10,202	0–69,744	0.960
Positive	29	7,040	0–55,320
Her2 status
Negative	25	7,040	0–69,744	0.834
Positive	37	8,707	0–59,528
Ki-67 expression, %
<20	24	10,078	0–69,744	0.270
≥20	38	6,127	0–59,528

Her2, human epidermal growth factor receptor 2; IOD, integrated optical density; CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1.